Flammer Martina M.D.

INSM CMO Flammer sold 18,333 shares for $2.1M (May 13-14) under pre-arranged 10b5-1 plan; stock down 48.7% from 52-week high.

Flammer Martina M.D., Chief Medical Officer of INSMED Inc, executed three separate sales totaling 18,333 shares for $2,128,891.98 on May 13–14, 2026 at prices ranging from $112.76 to $117.54 per share. This sale reduced her holdings by 22.0% (from 83,243 to 64,910 shares) and was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-02-27, meaning the transactions were scheduled rather than discretionary. The current stock price of $109.14 reflects a 48.7% decline from the 52-week high of $212.75 and a 25.6% drop over the past 30 days. INSMED remains unprofitable (net income of $-163.6M in the latest reported period) despite strong revenue growth of 66.7% year-over-year, signaling operational challenges at a $23.7B market-cap company. The scheduled nature of the 10b5-1 plan removes any timing inference from this particular transaction; investors should focus on the company's deteriorating stock price relative to fundamentals rather than on the insider's individual sale decision.

CMO Flammer executes exercise-and-sell: 12,949 shares acquired and nearly all shares sold same-day at steep markup, realizing ~$1.3M proceeds.

Dr. Martina Flammer, Chief Medical Officer of Insmed, exercised 12,949 shares and then immediately sold 12,949 shares on the same day—a pattern that completely offsets her equity gain and locks in liquidity. The sale price significantly exceeded her exercise price, translating to approximately $1.3 million in total disposition proceeds. This represents her sixth and seventh open-market sales at Insmed over the past three years, as her trading activity has been exclusively selling (zero open-market purchases). Notably, all five of her prior sales at this company showed the stock declining afterward—a pattern of uniformly well-timed exits that suggests Flammer has consistently exited before downturns. The stock currently trades well below its 52-week high and has declined materially over the past month and quarter, while the company remains unprofitable despite strong revenue growth. The exercise-and-sell structure combined with her consistent exit timing suggests a pattern of disciplined liquidity management rather than a vote of confidence in the company's near-term direction.

CMO Martina M.D. Flammer sold 8,777 shares at blended avg $154.70 for $1.4M on 2026-02-02/03, retaining 84.1K shares post-transaction.

Chief Medical Officer Flammer executed 6 separate sales totaling 8,777 shares for $1,357,796.17 over two trading days, with transaction prices ranging from $152.06 to $156.86—above the current price of $152.44 but significantly below the 52-week high of $211.41. Despite the sales, Flammer retained 84,112 shares (84.1K shares) post-transaction, representing a 9.4% reduction in her prior position of 92,889 shares (92.9K shares). The company is currently unprofitable (full-year net income was negative and latest quarter net income was $-370,021,000.00), though revenue grew 19.2% year-over-year to $142,342,000.00 (latest quarter). Flammer's prior trades at INSM are all recent (January 2026) and outcomes are not yet measurable at the 90-day horizon, limiting insight into her timing accuracy at this specific ticker.

CMO Flammer sold 16,530 shares for $2,877,139.26 across 7 transactions Jan 6-8, reducing holding 16.0%.

Flammer Martina M.D., Chief Medical Officer at INSMED Inc, executed 7 separate sales totaling 16,530 shares for $2,877,139.26 between January 6–8, 2026, at prices ranging from $173.33 to $175.84 (blended average $174.06). This represents a 16.0% reduction in her holdings, from 103.3K to 86.8K shares post-transaction. The timing context is noteworthy: these sales occurred within days of five prior sells at the same ticker on January 5, indicating sustained liquidation activity. Currently the stock trades at $170.27, down 19.5% from its 52-week high of $211.41 and down 12.3% over the past 30 days, meaning the execution prices on January 6–8 captured a higher valuation than the current market. Across her broader cross-ticker track record, Flammer's 20 prior open-market sells have shown a 90-day well-timed rate of 0.00% (historically her sells have not preceded declines), and her most recent same-ticker activity at INSM on January 5 remains too recent to measure outcome. The company posted $142.3M in latest-quarter revenue (+19.2% annual growth) but a negative net income of $-370.0M and remains unprofitable on a full-year basis, creating a mismatch between revenue momentum and current profitability that warrants monitoring.

CMO Martina Flammer sells 12.3K INSM shares (11.5% of holdings) for $2.1M on 2026-01-05

Martina Flammer, Chief Medical Officer at INSMED Inc, executed 7 separate sales totaling 12,303 shares for $2,108,506.58 on 2026-01-05, reducing her position from 107,057 shares to 94,754 shares (11.5% reduction). The sales ranged from $169.29 to $175.73 per share with a blended average of $171.38, occurring as the stock trades at $175.07 (currently -17.2% from its 52-week high of $211.41 and down 14.2% over the past 30 days). Across her full cross-ticker insider transaction history, Flammer's 20 prior sells achieved a 0.00% well-timed rate at the 90-day mark with an average 90-day return of +53.1%, indicating her prior sell decisions have not systematically preceded stock declines. At this specific ticker, 4 of her 5 prior trades occurred on 2026-01-06 (one day after this filing) with outcomes not yet measurable, while her most recent same-ticker sell on 2025-12-01 has registered a -15.9% 30-day return; however, neither track record scope provides clear directional evidence for this transaction. The company remains unprofitable (latest full-year net income of $-370,021,000.00) despite 19.2% annual revenue growth and a $37.3B market cap, creating a backdrop of contrasting signals.

CMO Flammer sold 8,895 shares for $1,841,100.65 on 2025-12-01 near 52-week highs; retains 83,111 shares.

Martina M.D. Flammer, Chief Medical Officer, executed 3 separate sales totaling 8,895 shares for $1,841,100.65 at prices ranging from $205.98 to $207.73 on 2025-12-01, reducing her holdings from 92,006 to 83,111 shares (-9.7%). The transaction occurred near the 52-week high of $211.41 (current price $206.78 is -2.2% from that peak), following a strong 30-day rally of +11.0% and a 90-day run of +45.1%. At the same ticker (INSM), Flammer's one measurable prior sale on 2025-09-02 posted a 90-day return of +46.8%, indicating the stock rose after that sale—a poorly-timed outcome relative to her sell decision. The company remains unprofitable with annual net income of $-370,021,000.00 despite revenue growth of +19.2% year-over-year, adding fundamental context to insider liquidation activity at elevated price levels.

CMO Flammer sells 31.2K shares for $5.9M at $189.68 blended avg; exits 27.3% of holdings as stock nears 52-week high.

Martina M.D. Flammer, Chief Medical Officer at INSM, executed 4 separate sales on 2025-11-11 totaling 31,226 shares for $5,922,794.88 at prices ranging from $188.38 to $191.04, with a blended average price of $189.68. The divestiture reduces her holdings by 27.3%, from 114,337 shares to 83,111 shares post-transaction. The stock is currently trading at $190.96, just 1.8% below its 52-week high of $194.39, and has posted a 30-day gain of 18.3% and 90-day gain of 49.4%, suggesting she sold into a period of strong momentum. Across her prior INSM trades (5 prior sales on 2025-09-02), her 30-day post-sale returns ranged from 4.6% to 8.2%, all positive, indicating the stock moved upward after her previous sales at this ticker; notably, 0 of 0 prior INSM sales at the 90-day horizon were well-timed (none preceded a decline). The company reported negative net income of $-370.0M against quarterly revenue of $142.3M, though annual revenue growth stands at 19.2%, and the $40.7B market cap positions this as a large-cap biotech with significant unprofitability.

CMO Martina Flammer sells 186.6K shares for $26.9M (blended $144.34); reduces holdings 69.2% to 83.1K shares.

Flammer executed 6 separate sales on 2025-09-02 totaling 186,648 shares for $26,941,272.29, reducing her INSM holdings by 69.2% from 269,759 shares to 83,111 shares post-transaction. The transaction occurred while the stock was at -1.9% from its 52-week high of $145.30, and the blended average price of $144.34 aligns closely with recent highs. At the same-ticker level, Flammer's prior two 90-day measurable outcomes (2025-05-15 and 2025-05-16 sells) both showed positive 90-day returns of 87.7% and 89.2% respectively, meaning the stock continued to appreciate after her sales—a pattern of poorly-timed exits at this ticker. The company remains unprofitable with net income of -$321.7M on revenue of $107.4M (latest quarter), though annual revenue growth is +19.2%. The magnitude of this single-day divestiture—nearly 187K shares at near-peak valuations—coupled with the consistent post-sale appreciation observed in her prior INSM transactions, warrants close monitoring of forward guidance and execution commentary.

Chief Medical Officer Martina M.D. Flammer sells 8,715 shares (8.7K) of INSM at $109.50; holding drops to 83,111 shares.

Martina M.D. Flammer, Chief Medical Officer of INSMED Inc, sold 8,715 shares at $109.50 for a total value of $954,292.50, reducing her position from 91,826 shares to 83,111 shares (-9.5% reduction). The sale occurred near the 52-week high (current price $111.26 is -0.3% from the $111.61 peak), and the stock has appreciated +14.8% over 30 days and +69.5% over 90 days. However, across Flammer's cross-ticker track record of 20 prior sells, her timing has been poor: her average 90-day return after sells was -5.6%, with only a 64.29% well-timed rate. At the same ticker, her prior five sells at INSM (most recent in June and May 2025) have all shown positive 30-day returns (+3.9% to +50.8%), yet measurable 90-day outcomes are not yet available; none of her prior INSM sales reached the 90-day mark in a timely manner to assess downside protection. The company remains unprofitable (full-year net income of $-256.6M) despite revenue growth of +19.2%, which provides fundamental context for executive transaction activity.

INSM CMO Flammer sells 45,163 shares ($4.1M) across two days; retains 83,111 shares post-transaction.

Martina M.D. Flammer, INSM's Chief Medical Officer, executed 2 separate sales totaling 45,163 shares for $4,117,067.10 on 2025-06-10 and 2025-06-11 at a blended average price of $91.16, reducing her holdings by 35.2% to 83,111 shares. The sales occurred when INSM was trading near its 52-week high—just 1.1% below the peak of $97.98—and follow a 47.4% surge over the prior 30 days. At the same ticker, Flammer's prior measurable sale outcome (2025-02-10) showed a 90-day decline of 15.5%, indicating that sell was well-timed; however, her most recent prior sales at INSM (May 13–16) are still within or approaching their outcome-measurement windows with limited data. Across her cross-ticker trading history, she has executed 20 prior sells with a 56.25% well-timed rate at the 90-day mark, suggesting modest predictive value but not a dominant pattern. INSM itself remains unprofitable despite 19.2% annual revenue growth, a context that may inform position-adjustment decisions by its clinical leadership.